DK0853627T3 - Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi - Google Patents

Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi

Info

Publication number
DK0853627T3
DK0853627T3 DK96923234T DK96923234T DK0853627T3 DK 0853627 T3 DK0853627 T3 DK 0853627T3 DK 96923234 T DK96923234 T DK 96923234T DK 96923234 T DK96923234 T DK 96923234T DK 0853627 T3 DK0853627 T3 DK 0853627T3
Authority
DK
Denmark
Prior art keywords
endotoxemia
treatment
prevention
liposaccharides
substituted liposaccharides
Prior art date
Application number
DK96923234T
Other languages
English (en)
Inventor
J Christ William
P Rossignol Daniel
Seiichi Kobayashi
Tsutomu Kawata
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23833509&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0853627(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DK0853627T3 publication Critical patent/DK0853627T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
DK96923234T 1995-06-05 1996-06-05 Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi DK0853627T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/461,675 US5750664A (en) 1995-06-05 1995-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia
PCT/US1996/009578 WO1996039411A1 (en) 1995-06-05 1996-06-05 Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Publications (1)

Publication Number Publication Date
DK0853627T3 true DK0853627T3 (da) 2004-06-01

Family

ID=23833509

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96923234T DK0853627T3 (da) 1995-06-05 1996-06-05 Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi

Country Status (21)

Country Link
US (8) US5681824A (da)
EP (1) EP0853627B1 (da)
JP (3) JP4009318B2 (da)
KR (1) KR100416335B1 (da)
CN (1) CN1067082C (da)
AT (1) ATE258185T1 (da)
AU (1) AU707779C (da)
CA (1) CA2223140C (da)
DE (1) DE69631376T2 (da)
DK (1) DK0853627T3 (da)
ES (1) ES2214543T3 (da)
HU (1) HU221342B1 (da)
IL (2) IL122251A0 (da)
MX (1) MX9709502A (da)
NO (1) NO310239B1 (da)
NZ (1) NZ312299A (da)
PT (1) PT853627E (da)
RU (1) RU2170738C2 (da)
TW (1) TW366345B (da)
WO (1) WO1996039411A1 (da)
ZA (1) ZA964666B (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6417172B1 (en) * 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
CN1150001C (zh) * 1996-07-03 2004-05-19 卫材株式会社 含有脂质a类似物的注射剂及其制备方法
EP1111390A4 (en) * 1998-09-01 2007-11-14 Eisai R&D Man Co Ltd METHOD FOR EVALUATING INJECTIONS CONTAINING LIPID A ANALOGS
ATE501760T1 (de) * 1999-01-14 2011-04-15 Eisai R&D Man Co Ltd E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
TW527358B (en) * 1999-02-10 2003-04-11 Sankyo Co Ether type lipid A1 position carboxylic acid analogue
AU2001229479A1 (en) * 2000-01-14 2001-07-24 Eisai Co. Ltd. Prevention and treatment of endotoxemia and related complications associated with surgery
US20050101549A1 (en) * 2000-01-14 2005-05-12 Melvyn Lynn Prevention and treatment of endotoxemia and related complications associated with surgery
CA2400371C (en) * 2000-02-18 2009-12-08 Eisai Co. Ltd. Methods to prepare micelles comprising amphiphilic lipopolysaccharide compounds
US6861512B2 (en) * 2000-03-01 2005-03-01 Eisai Co., Ltd. Separation of olefinic isomers
US20030105033A1 (en) * 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
AU2001275520A1 (en) * 2000-06-09 2001-12-17 Eisai Co. Ltd. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
JPWO2002088062A1 (ja) * 2001-04-23 2004-08-12 エーザイ株式会社 アルコール誘導体の製造方法
WO2002088072A1 (fr) * 2001-04-23 2002-11-07 Eisai Co., Ltd. Procede de preparation de composes d'alkylene
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
WO2002094019A1 (en) * 2001-05-22 2002-11-28 Eisai Co., Ltd Highly purified antiendotoxin compound
DE10125179A1 (de) * 2001-05-23 2002-12-05 Laves Ralph Georg Verwendung von LPS zur Behandlung intestinaler Entzündungsprozesse
WO2003013440A2 (en) * 2001-08-10 2003-02-20 Eisai Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
AU2002362138A1 (en) * 2001-12-11 2003-06-23 Eva Lorenz Toll-like receptor 4 mutations
AU2002950657A0 (en) * 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
WO2004058788A1 (ja) * 2002-12-24 2004-07-15 Sankyo Company, Limited 右糖グルコースリピドa類縁体
ES2639812T3 (es) * 2003-01-06 2017-10-30 Corixa Corporation Ciertos compuestos de fosfato de aminoalquil glucosaminida y sus usos
WO2004074303A2 (en) * 2003-02-20 2004-09-02 Eisai Co, Ltd. Reagents and methods for preparing lps antagonist b1287 and stereoisomers thereof
MXPA05009428A (es) * 2003-03-05 2005-12-12 Eisai Co Ltd Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2005027826A2 (en) * 2003-07-14 2005-03-31 Eisai, Co, Ltd. Methods and treating severe acute respiratory syndrome
WO2005059517A2 (en) 2003-12-16 2005-06-30 University Of Massachusetts Toll-like receptor assays
TW200530260A (en) * 2004-01-08 2005-09-16 Sankyo Co Levorotary glucose lipid a analogs
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
US7976852B2 (en) * 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
EP1895842A4 (en) * 2005-06-17 2009-06-03 Univ Rochester METHOD AND COMPOSITIONS FOR EXPANDING THE IMMUNE MEMORY BY BLOCKING INTRA-HEPATIBLE ACTIVATED T-CELL ERASURE
JP5118968B2 (ja) * 2005-08-31 2013-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 リピッドａ類縁体の製造方法
US20090149647A1 (en) * 2005-08-31 2009-06-11 Eisai R&D Management Co., Ltd. Process for production of lipid a analogue
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
WO2008059307A2 (en) * 2006-11-16 2008-05-22 Om Pharma Functionalized beta 1,6 glucosamine disaccharides and process for their preparation
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US8207144B2 (en) 2006-11-22 2012-06-26 Eisai R & D Management Co., Ltd. Sodium salt of disaccharide compound, production method and use of same
GB2450580B (en) 2006-11-23 2010-04-14 Cadila Pharmaceuticals Ltd Poly-TLR antagonist
US20110201569A1 (en) * 2009-09-16 2011-08-18 Heidi Ehrentraut Methods For Treating Myocardial Disorders
WO2011038537A1 (zh) * 2009-09-29 2011-04-07 上海南方基因科技有限公司 败血症以及败血症休克的预测、预防和治疗方法及试剂盒
GB201013785D0 (en) 2010-08-17 2010-09-29 Ucl Business Plc Treatment
JP2012246470A (ja) 2011-05-31 2012-12-13 Sharp Corp 半導体ナノ粒子の製造方法、半導体ナノ粒子、ならびにこれを用いた蛍光体
KR102086729B1 (ko) * 2011-12-22 2020-03-10 나노코 테크놀로지스 리미티드 표면 변형된 나노입자들
KR20140139063A (ko) 2012-03-28 2014-12-04 유니버시티 오브 매릴랜드, 발티모어 오르토믹소바이러스 감염 치료를 위한 에리토란 또는 그의 제약학상 허용가능한 염의 투여
WO2014113048A1 (en) * 2013-01-18 2014-07-24 Loma Linda University Compositions and methods for diagnosing and treating sepsis
AU2014287002A1 (en) 2013-07-11 2016-02-11 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
US9584991B1 (en) * 2014-06-19 2017-02-28 Isaac S. Daniel Method of communicating and accessing social networks using interactive coded messages
JP2019513137A (ja) * 2016-03-30 2019-05-23 アユヴィス リサーチ インク．Ａｙｕｖｉｓ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． 新規組成物及び治療方法
SI3795576T1 (sl) * 2016-09-14 2023-08-31 Genomatica, Inc. 1,3-maščobne spojine diola in njihovi glikozilirani derivati
US11185554B2 (en) * 2016-09-16 2021-11-30 Eisai R&D Management Co., Ltd Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease
AU2019400340A1 (en) 2018-12-17 2021-05-20 Eisai R&D Management Co., Ltd. Formulation comprising liposomes
WO2021207218A1 (en) 2020-04-06 2021-10-14 Eisai R&D Management Co., Ltd. Treatment of nidovirales infection with eritoran
CN113527396B (zh) * 2020-04-17 2024-02-02 上海医药工业研究院 一种疫苗佐剂mpla的中间体、合成及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495346A (en) * 1981-03-30 1985-01-22 Wisconsin Alumni Research Foundation Method of preparing a disaccharide
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
JPS6153295A (ja) * 1984-08-24 1986-03-17 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体
US5066794A (en) * 1984-08-24 1991-11-19 Daiichi Pharmaceutical Co., Ltd. Process for preparing a disaccharide derivative
NL8601551A (nl) * 1985-06-28 1987-01-16 Sandoz Ag Nieuwe saccharides, hun bereiding en farmaceutische samenstellingen, die hen bevatten.
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
JP2839916B2 (ja) * 1989-10-20 1998-12-24 三共株式会社 リピドａ３位エーテル類縁体
PT94481B (pt) 1989-12-11 1997-02-28 Sankyo Co Processo para a preparacao de analogos de lipidos a tendo imunoactividade e actividade anti-tumoral
JP2847319B2 (ja) 1990-05-18 1999-01-20 イビデン株式会社 電子部品搭載用多層ボンディング基板
JP3040847B2 (ja) 1990-06-22 2000-05-15 三共株式会社 リピドｘ類縁体
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
JP3135990B2 (ja) 1992-07-31 2001-02-19 沖電気工業株式会社 パリティ付加回路
US5413785A (en) * 1993-01-27 1995-05-09 New England Deaconess Hospital Corp. Methodology employing lactobacillus GG for reduction of plasma endotoxin levels circulating in-vivo
US5681824A (en) 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6417172B1 (en) 1995-06-05 2002-07-09 Eisai Co., Ltd. Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
JP4235193B2 (ja) 2005-06-07 2009-03-11 日本電信電話株式会社 イベント履歴蓄積装置、イベント情報検証装置、イベント履歴蓄積方法、イベント情報検証方法およびイベント情報処理システム

Also Published As

Publication number Publication date
AU6380296A (en) 1996-12-24
KR100416335B1 (ko) 2004-07-27
US5681824A (en) 1997-10-28
DE69631376D1 (de) 2004-02-26
JP4009318B2 (ja) 2007-11-14
CA2223140A1 (en) 1996-12-12
IL122251A0 (en) 1998-04-05
US20100227835A1 (en) 2010-09-09
US20020028927A1 (en) 2002-03-07
CN1192216A (zh) 1998-09-02
NO975644L (no) 1998-02-04
CN1067082C (zh) 2001-06-13
HUP9802662A3 (en) 1999-06-28
JP2011121970A (ja) 2011-06-23
ATE258185T1 (de) 2004-02-15
ES2214543T3 (es) 2004-09-16
MX9709502A (es) 1998-10-31
DE69631376T2 (de) 2004-11-11
US5750664A (en) 1998-05-12
AU707779C (en) 2001-12-06
US20030144503A1 (en) 2003-07-31
US7994154B2 (en) 2011-08-09
PT853627E (pt) 2004-05-31
JP4712001B2 (ja) 2011-06-29
KR19990022104A (ko) 1999-03-25
US20080214802A1 (en) 2008-09-04
AU707779B2 (en) 1999-07-22
JPH11506793A (ja) 1999-06-15
TW366345B (en) 1999-08-11
ZA964666B (en) 1997-03-11
NZ312299A (en) 1999-08-30
US5935938A (en) 1999-08-10
IL149971A (en) 2010-04-29
WO1996039411A1 (en) 1996-12-12
NO975644D0 (no) 1997-12-04
US6184366B1 (en) 2001-02-06
NO310239B1 (no) 2001-06-11
CA2223140C (en) 2008-08-05
EP0853627B1 (en) 2004-01-21
HUP9802662A2 (hu) 1999-05-28
EP0853627A4 (en) 1998-10-07
US7737129B2 (en) 2010-06-15
JP2007269812A (ja) 2007-10-18
HU221342B1 (en) 2002-09-28
EP0853627A1 (en) 1998-07-22
RU2170738C2 (ru) 2001-07-20

Similar Documents

Publication Publication Date Title
DK0853627T3 (da) Substituerede liposaccharider, som er egnede til behandling og forebyggelse af endotoksæmi
FI960780A0 (fi) Nolla intermediaarinen frekvenssivastaanotin
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
BR9808491A (pt) Compostos calcilìticos
DE950162T1 (de) Mischgaskälteverfahren
DE69414874T2 (de) Kryptographischer empfänger
ID23374A (id) Halogenopirimidin
DE69607387T2 (de) Tragbare küche für camping
ES1017793Y (es) Aparato refrigerador, especialmente frigorifico domestico.
TR199701298T1 (xx) Tetralinler.
DE59510131D1 (de) Imidazopyridin-azolidinone
DE69403659T2 (de) Start-stop-empfänger
NO993180D0 (no) N-(pyridinylamino)isoindoler og beslektede forbindelser
FR2717185B1 (fr) Microfiltration de la bière.
ES1030365Y (es) Nevera portatil.
NO960324D0 (no) Mottaker for selektivt anrop
NO960796D0 (no) Benzotiofenonforbindelser, mellomprodukter, sammensetninger og fremgangsmåter
DE69607342D1 (de) Faltbares, vierseitiges gestell
ES1031366Y (es) Cuna convertible.
TR199801087T2 (xx) 4,10 �- diasetoksi-2alfa-Benzoiloksi- 5 �, 20 epoksi-1- hidroksi-9- okso-19- norsiklopropa(G) taks-11- en- 13alfa-il
ES1031141Y (es) Somier de laminas oscililantes, transformables en fijas.
DE29619157U1 (de) Nierengurt
ITLU930002A1 (it) Ricevitore reazionato accoppiato.
ES1028150Y (es) Pieza de lastre utilizada en cinturones de actividades subacuaticas.
ES1031002Y (es) Atraccion de feria autotransportable.